It has been agreed that Merck will market the drugs in Europe, Russia and Turkey and will pay $500 million to J&J, who will market them in Canada, Central and South America, Africa, the Middle East and the Asia-Pacific region. Merck will then split the profits from the sales of the drugs.
The dispute originally arose after Merck acquired Schering-Plough which had a marketing agreement with J&J.
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.